

Financial news for RNA dated on 2015-01-30: Prosensa Announces Intent to Voluntarily Delist From NASDAQ

Financial news for RNA dated on 2014-12-03: BioMarin Shares Volatile Following Appearance by CEO Bienaime on CNBC's Fast Money, Discussed Prospects for Prosensa Deal, Drug Approval

Financial news for RNA dated on 2014-11-25: Benzinga's Top Downgrades

Financial news for RNA dated on 2014-11-25: KBC Securities Downgrades Prosensa To Hold

Financial news for RNA dated on 2014-11-25: KBC Securities Downgrades Prosensa to Hold, Raises PT to \$19.80

Financial news for RNA dated on 2014-11-24: Benzinga's M&A Chatter for Monday November 24, 2014

Financial news for RNA dated on 2014-11-24: Mid-Afternoon Market Update: Trina Solar Drops After Quarterly Results; Tetrphase Pharmaceuticals Shares Spike Higher

Financial news for RNA dated on 2014-11-24: Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters Shares Jump On Acquisition News

Financial news for RNA dated on 2014-11-24: Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire Prosensa For \$17.75/Share

Financial news for RNA dated on 2014-11-24: Mid-Day Gainers From November 24: Prosensa, Cimatron, Platinum Underwriters, Five Prime Therapeutics, Tetrphase Pharmaceuticals

Financial news for RNA dated on 2014-11-24: Benzinga's Volume Movers

Financial news for RNA dated on 2014-11-24: Stocks Hitting 52-Week Highs

Financial news for RNA dated on 2014-11-24: Morning Market Movers

Financial news for RNA dated on 2014-11-24: BioMarin Pharmaceuticals To Acquire Prosensa

Financial news for RNA dated on 2014-11-24: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-11-24: US Stock Futures Up Ahead Of Economic Data

Financial news for RNA dated on 2014-11-24: Prosensa Holding Shares Rise 61% Premarket on BioMarin Acquisition Announcement; Sarepta Shares Up 11%

Financial news for RNA dated on 2014-11-24: BioMarin to Acquire Prosensa for \$17.75/Share

Financial news for RNA dated on 2014-11-24: BioMarin to Pay Up to \$840M for Prosensa

Financial news for RNA dated on 2014-11-17: CORRECTION: Prosensa Reports Q3 EPS of \$(0.23), Inline

Financial news for RNA dated on 2014-11-17: Prosensa Reports Q3 EPS of \$(0.23) EURO vs \$(0.23) EURO Est

Financial news for RNA dated on 2014-11-17: Earnings Scheduled For November 17, 2014

Financial news for RNA dated on 2014-10-27: Mid-Afternoon Market Update: NQ Mobile Climbs On SEC Filing; Huntsman Shares Slide

Financial news for RNA dated on 2014-10-27: Midday Gainers From October 27: Micron Technology, Regulus Therapeutics, CyberArk Software And More

Financial news for RNA dated on 2014-10-27: Mid-Day Market Update: Micron Gains On Buyback Announcement; Sarepta Shares Dip

Financial news for RNA dated on 2014-10-27: Mid-Morning Market Update: Markets Down; Merck Posts Upbeat Earnings

Financial news for RNA dated on 2014-10-27: Benzinga's Volume Movers

Financial news for RNA dated on 2014-10-27: Morning Market Movers

Financial news for RNA dated on 2014-10-27: Sarepta Therapeutics Shares Drop, Prosensa Shares Rise

Financial news for RNA dated on 2014-10-27: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-10-27: Shares of Prosensa Holding Rise 13% Premarket on FDA Requirement of Additional Data from Sarepta on Eteplirsen; Sarepta Shares Fall 38%

Financial news for RNA dated on 2014-10-20: JP Morgan Upgrades Prosensa to Overweight, Raises PT to \$18.00

Financial news for RNA dated on 2014-10-13: KBC Partners Upgrades Prosensa to Buy, Raises PT to \$17.00

Financial news for RNA dated on 2014-10-10: Prosensa Reports Commencement of NDA Submission to FDA for Drisapersen

Financial news for RNA dated on 2014-10-06: Ebola Sector Shake Out Leaves Chimerix Inc On Top

Financial news for RNA dated on 2014-09-24: Benzinga's Top Initiations

Financial news for RNA dated on 2014-09-24: Credit Suisse Initiates Prosensa With Neutral

Financial news for RNA dated on 2014-09-24: Credit Suisse Initiates Coverage on Prosensa at Neutral, Announces \$9.00 PT

Financial news for RNA dated on 2014-09-17: Prosensa Reports Commencement of North American Re-Dosing Related to Drisapersen

Financial news for RNA dated on 2014-09-08: Morning Market Movers: The Bank of Kentucky Financial Corp., BB&T Corporation & More

Financial news for RNA dated on 2014-09-08: Prosensa: Results Confirms Positive Outcome Of Demand II Study, Which Met Primary Endpoint, With No Reported Major Safety Concerns - DJ

Financial news for RNA dated on 2014-07-28: Roth Capital Upgrades Prosensa to Buy, Raises PT to \$17.00

Financial news for RNA dated on 2014-07-07: Prosensa Release Discloses Filing of Mixed Shelf Registration for Up to \$150M

Financial news for RNA dated on 2014-07-03: Prosensa Holding Files Up to \$150M Mixed Shelf

Financial news for RNA dated on 2014-06-27: Prosensa Awarded \$200,000 Research Grant from PPMD

Financial news for RNA dated on 2014-06-23: Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

Financial news for RNA dated on 2014-06-18: Roth Capital Initiated Coverage on Prosensa at Neutral, Announced \$12.00 PT

Financial news for RNA dated on 2014-06-04: Benzinga's Top Upgrades

Financial news for RNA dated on 2014-06-04: KBC Securities Upgrades Prosensa to Accumulate, Raises PT to \$11.00

Financial news for RNA dated on 2014-06-03: Morning Market Movers

Financial news for RNA dated on 2014-06-03: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-06-03: Prosensa Announces Regulatory Path Forward for Drisapersen as a Potential Treatment for DMD

Financial news for RNA dated on 2014-05-23: Morning Market Movers Friday, May 23, 2014

Financial news for RNA dated on 2014-05-23: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-05-20: Earnings Scheduled For May 20, 2014

Financial news for RNA dated on 2014-05-02: KBC Upgrades Prosensa to Hold

Financial news for RNA dated on 2014-05-01: Prosensa Provides Update on Drisapersen

Financial news for RNA dated on 2014-04-21: Morning Market Movers

Financial news for RNA dated on 2014-04-21: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-04-07: Prosensa Shares Pullback After-Hours; Stock was Not Mentioned by Yaron Werber on CNBC as had been Expected

Financial news for RNA dated on 2014-04-07: Adam Feuerstein Tweet: 'Drinking game: Do a shot each time Yaron Werber recommends \$RNA on Fast Money tonight'

Financial news for RNA dated on 2014-03-18: Morning Market Movers

Financial news for RNA dated on 2014-03-18: Prosensa Holdings Shares Surge 20+%, Earlier Reported FY13 Loss of EUR0.51 vs Estimated Loss of EUR0.46/Share, Sales EUR8.9M vs EUR10.7M Est.

Financial news for RNA dated on 2014-03-18: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-03-18: Earnings Scheduled For March 18, 2014

Financial news for RNA dated on 2014-03-17: Prosensa Announces 48-Week Data from Phase II Placebo-Controlled Study Of Drisapersen In 51 DMD Boys

Financial news for RNA dated on 2014-03-05: Citigroup Maintains Neutral on Prosensa, Raises PT to \$7.40

Financial news for RNA dated on 2014-02-11: Wedbush Upgrades Prosensa to Outperform, Raises PT to \$12.00

Financial news for RNA dated on 2014-02-11: Benzinga's Top #PreMarket Gainers

Financial news for RNA dated on 2014-01-27: UPDATE: JMP Downgrades Sarepta, Data Considered Weak and Overstated

Financial news for RNA dated on 2014-01-21: Needham Upgrades Sarepta, Says Stock Undervalued Even In Conservative Case

Financial news for RNA dated on 2014-01-16: Electromed Shares Move Higher; May be Moving in Sympathy with Prosensa

Financial news for RNA dated on 2014-01-16: Prosensa Shares Resume, Now Up 35%

Financial news for RNA dated on 2014-01-16: Prosensa Halted on Circuit Breaker

Financial news for RNA dated on 2014-01-16: Prosensa Reports Initial Findings from Further Clinical Data Analyses of Drisapersen for Treatment of Duchenne Muscular Dystrophy

Financial news for RNA dated on 2014-01-13: Prosensa to Provide Update to on Drisapersen

Financial news for RNA dated on 2014-01-13: Morning Market Losers

Financial news for RNA dated on 2014-01-13: Benzinga's Top #PreMarket Losers

Financial news for RNA dated on 2013-12-19: Prosensa Comments on Drisapersen Program Update

Financial news for RNA dated on 2013-11-19: Citigroup Maintains Neutral on Prosensa, Lowers PT to \$4.00

Financial news for RNA dated on 2013-09-30: 13G Filing from James Flynn Shows 9.21% Stake in Prosensa

Financial news for RNA dated on 2013-09-24: UPDATE: J.P. Morgan Downgrades Prosensa Following Drisapersen DEMAND-III Study Failure

Financial news for RNA dated on 2013-09-24: Benzinga's Top Downgrades

Financial news for RNA dated on 2013-09-24: JP Morgan Downgrades Prosensa to Neutral, Lowers PT to \$6.50

Financial news for RNA dated on 2013-09-23: UPDATE: Wedbush Downgrades Prosensa Following Bad News About Drisapersen

Financial news for RNA dated on 2013-09-23: KBC Downgrades Prosensa to Hold, Lowers PT to \$10.00

Financial news for RNA dated on 2013-09-23: Wedbush Downgrades Prosensa to Neutral, Lowers PT to \$7.00

Financial news for RNA dated on 2013-09-20: Piper Jaffray Upgrades Sarepta Therapeutics, Inc. to Overweight, Raises PT to \$58.00

Financial news for RNA dated on 2013-09-20: Stocks Hitting 52-Week Lows

Financial news for RNA dated on 2013-09-20: PreMarket Info Recap for September 20, 2013: Lining Up for the New iPhone

Financial news for RNA dated on 2013-09-20: Benzinga's Top Pre-Market Losers

Financial news for RNA dated on 2013-09-20: UPDATE: Prosensa Shares Fall 68% Pre-Market on Failed Duchenne Muscular Dystrophy Study, Sarepta Falls 8%

Financial news for RNA dated on 2013-09-20: Prosensa Shares Fall 23% on Light Volume on Phase III Duchenne Muscular Dystrophy Results

Financial news for RNA dated on 2013-09-20: Sarepta Shares Rise 15% Pre-Market on Failure of Glaxo, Prosensa Duchenne Muscular Dystrophy Treatment

Financial news for RNA dated on 2013-09-20: GSK Prosensa Announce Primary Endpoint Not Met in Phase III Duchenne Muscular Dystrophy Study of Drisapersen

Financial news for RNA dated on 2013-08-05: Market Wrap For Monday, August 5: Stocks Close Mixed; Nasdaq Rises, Dow And S&P Fall Modestly

Financial news for RNA dated on 2013-07-23: UPDATE: J.P. Morgan Initiates Prosensa at Overweight on Strong PII Results

Financial news for RNA dated on 2013-07-23: Wedbush Initiated Coverage on Shares of Prosensa with an Outperform Rating and \$50 Price Target